Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...
Celltrion's Steqeyma completes rollout in major European markets, intensifying competition in the ustekinumab market. FDA approved Steqeyma in December 2024 for inflammatory conditions ...
Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback